BriaCell announces public offering of shares and warrants

PHILADELPHIA and VANCOUVER, British Columbia - BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) (TSX: BCT), a clinical-stage biotechnology firm specializing in immunotherapies for cancer treatment with a current market capitalization of $2.5 million and trailing twelve-month revenue of $0.32 million, has declared its intention to conduct an underwritten public offering of common shares and warrants. The completion and specifics of the offering, including its size and terms, are contingent on market conditions, and there is no certainty of its finalization.

ThinkEquity is serving as the exclusive book-running manager for the offering. According to InvestingPro data, BriaCell has been quickly burning through cash and experiencing high price volatility, with its stock declining over 80% year-to-date. The company plans to allocate the net proceeds toward working capital, general corporate purposes, and furthering its business objectives. The securities are being offered via a shelf registration statement on Form S-3, which was filed with the U.S. Securities and Exchange Commission (SEC) on January 22, 2024, and became effective on January 31, 2024.

Investors can access the preliminary prospectus supplement and the accompanying prospectus, which detail the terms of the offering, on the SEC's website. These documents can also be obtained from ThinkEquity's offices. Prospective investors are encouraged to read these materials fully, along with other documents filed by the company with the SEC, to gain a comprehensive understanding of BriaCell and the offering.

BriaCell's press release includes forward-looking statements that involve significant risks and uncertainties. These statements are based on current expectations and are subject to factors that may cause actual results to differ materially. The company cautions that the statements should not be regarded as guarantees of future performance.

The information in this article is based on a press release statement and does not constitute an offer to sell or a solicitation of an offer to buy securities in any jurisdiction where such an offer, solicitation, or sale would be illegal prior to registration or qualification under the securities laws of that jurisdiction. For deeper insights into BriaCell's financial health and 10+ additional exclusive ProTips, visit InvestingPro.

In other recent news, BriaCell Therapeutics Corp. has announced the pricing of two public offerings. It has set the price for its $5 million share and warrant offering at $0.975 per share and associated warrant. The offering consists of 5,128,500 common shares and equivalent warrants, with the warrants having an exercise price of $0.85 per share. In a separate development, BriaCell has also priced an $8.5 million common share offering at $0.69 per share, offering 12,325,000 common shares. Both offerings' net proceeds are intended for general corporate purposes, working capital requirements, and furthering business objectives, with ThinkEquity serving as the sole placement agent for both transactions.

In recent developments, BriaCell has made significant strides in the development of its immunotherapy candidate Bria-PROS+™ for advanced prostate cancer. The U.S. Food and Drug Administration (FDA) has offered positive feedback and waived the requirement for animal toxicology and pharmacokinetic studies, simplifying the path for BriaCell to file an Investigational New Drug (IND) application and proceed with a Phase 1/2 clinical study of Bria-PROS+™. These recent developments underscore BriaCell's ongoing commitment to advancing immunotherapies in cancer care.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.